OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2022-12-31-accounts

Charity Registration No. 1182637 (England and Wales)

Charity Registration No. SC049948 (Scotland)

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2022

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees David Oxnam (Chair of Board of Trustees) Gayle Routledge Rachel Wilcox David Hobin Sarah Curtis Chief Executive Ashley Ball-Gamble Charity number 1182637 (England and Wales) SC049948 (Scotland) Company number CE016951 Operating name CCLG Principal address Century House 24 De Montfort Street Leicester LE1 7GB Auditor Newby Castleman LLP West Walk Building 110 Regent Road Leicester LE1 7LT Bankers HSBC Bank Plc 2-6 Gallowtree Gate Leicester LE1 1DA Scottish Widows Bank Plc PO Box 12757 67 Morrison Street Edinburgh EH3 8YJ CAF Bank Ltd 25 Kings Avenue Kings Hill Kent ME19 4JQ

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

Page
Trustees' report 1 - 10
Independent auditor's report 11 - 13
Statement of financial activities 14
Balance sheet 15
Statement of cash flows 16
Notes to the financial statements 17 - 31

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees of The Children’s Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity’s governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

OBJECTIVES AND ACTIVITIES

The objectives of The Children’s Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

  1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.

  2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.

  3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.

  4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland’s professional association for all those involved in the treatment and care of children with cancer (including leukaemia). Our multidisciplinary and multi-professional membership continues to grow. At the end of 2022, there were in excess of 1,300 members. In addition, we host Teenagers and Young Adults with Cancer (TYAC), a multidisciplinary and multi-professional membership association for those involved in the treatment and care of teenagers and young adults with cancer. At the end of 2022, there were more than 400 TYAC members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

The activities of our professional association and membership body include:

Our members are dedicated to ensuring that children and young people have a greater chance of survival and a better life after treatment.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We support children and young people with cancer and their families in a variety of different ways:

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured. But there are still some childhood cancers with a poor outlook, and some treatments can have longlasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments. We fund and support a variety of research into childhood cancers including:

We measure our success in achieving our objectives in a number of ways:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

ACHIEVEMENTS AND PERFORMANCE

Around 1,800 children (aged 0-14) and a further 2,300 teenagers and young adults (aged 15-25) are diagnosed with cancer each year in the UK. Although overall five-year survival for cancer in children and young people is now over 80%, for some cancers there have not been such dramatic improvements in survival, and even where treatment is successful, many survivors have to contend with life-long and life-limiting side effects. We continue to work towards the four main goals set out in our strategic plan, launched in 2018, and the goals of the TYAC strategic plan, launched in 2019, as detailed below. Highlights of our achievements during the year are set out under each of these strategic goals.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland’s professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children’s cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2022:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently.

Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2022:

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives. We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2022:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer.

Our Research Strategy outlines our exciting plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Teenagers and Young Adults with Cancer (TYAC)

Teenagers and Young Adults with Cancer (TYAC) is the professional association for those working in teenage and young adult (TYA) oncology. TYAC merged with CCLG in 2018, and in 2019 we launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in TYA cancer care, and support the development of professionals working in the field.

During the year, we continued to develop good practice guidance for professionals working with teenagers and young adults with cancer, launched a number of new networking and educational groups for professionals, including one focused on palliative and end of life care, and another jointly with CCLG focusing on developing ambulatory care services.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families, and improve treatment and care for children and young people with cancer. In 2022:

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public, we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer. We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials. Our supporters can sign up to make regular donations, or play our lottery which we launched in 2018.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities.

We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations.

Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities.

Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2022 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, funding from partner charities such as The Little Princess Trust to support research projects and legacy income. We are grateful to Young Lives vs Cancer, Teenage Cancer Trust and The Little Princess Trust for their support of specific areas of our work. We also benefitted from a grant from The Medical Research Council UK Government COVID Medical Research Charity Support Fund, a scheme designed to support fundraising medical research charities who fund early-career researchers in response to the COVID-19 pandemic.

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants. Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £2,642,141, compared with the year ending December 2021. We saw an increase in donations and fundraising income during the year, as well as an increase in income from charitable activities, including an increase investment in research by our partners The Little Princess Trust.

CCLG has a number of restricted funds. Internal records are kept according to requirements for restriction, i.e. disease-specific donations for research into a specific type of cancer, or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

Expenditure increased in 2022 by £2,373,420 compared to 2021. The primary reason for the increase was an increase in research funding, although we saw increased costs across much of our activity as a result of both the COVID-19 pandemic (e.g. increased costs of holding events as the events industry recovers) and the costof-living crises (e.g. increased energy costs).

We ended the year with an overall surplus of £537,840. There was a deficit in unrestricted income/expenditure of £100,510, which was planned and represents the Trustees commitment to invest reserves held above the level of our reserves policy into our charitable activities. There was a surplus in restricted income/expenditure of £638,350. Much of our restricted funding is for research, and often funds build over several years before being expended in significant amounts to fund research projects. We plan to spend a significant amount of restricted funds in the next 12 months.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. The COVID-19 pandemic has highlighted the importance of an appropriate reserves policy. It is important we continue to hold a level of reserves which can sustain our activity until we have a fuller picture of what post-pandemic fundraising might look like in the medium-term.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We have plans in place to ensure CCLG is ‘fit for the future’ and our reserves policy will ensure we are able to meet those plans. At the end of the year, we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £400,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs. Total reserves at 31 December 2022 were £2,460,897 of which £1,969,937 are restricted and £490,960 are unrestricted. As at 31 December 2022 the charity’s free reserves totalled £448,474, which is in line with the reserves policy. Given the current economic uncertainty, the trustees consider it prudent to continue to spend excess reserves on its charitable activities, while keeping the reserves policy under review. The trustees consider that this ensures that CCLG is ‘fit for the future’.

Our restricted reserves appear high, at £1,969,937 at the end of 2022. Much of our restricted income is raised by families, ring-fenced for research into specific types of childhood cancer. Research requires significant investment, and thus many of our funds grow over the course of several years before a large sum of money is awarded in the form of a research grant. Our restricted reserves comprise a large number of specific restricted funds which are ring-fenced to a specific purpose, and therefore cannot be used for general activities. Levels of funds are reviewed on a regular basis and spent on charitable activities as soon as sufficient funds are available. We are planning to invest a significant amount of restricted reserves into research during 2023.

Investment policy

The Trustees previously reviewed our plans for investments to consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the ongoing uncertainty of the financial impact of the COVID19 pandemic, the cost-of-living crisis, high inflation, and future grant commitments, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives for children and young people with cancer, and their families, as the ultimate beneficiaries. As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and providing specialist advice to commissioners of healthcare services and others. The CCLG executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice. The CCLG executive is a committee comprised of elected members of the CCLG professional body, along with the CEO, who have delegated authority from the Trustees for deciding and implementing the strategy of the organisation as it relates to the clinical, research and professional elements of our work.

Key planned activity for the next 12 months includes:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children’s Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. In 2019, a new CIO (registration number 1182637) was formed, with the activities, assets and liabilities of the previous charity transferred to the CIO.

The charity’s governing instrument is the Constitution and the CIO was first registered in February 2019. In 2020, the CIO became registered with the Scottish Charity Regulator (registration number SC049948).

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise. The board of trustees meets quarterly and is supported by staff. Four meetings were held in 2022.

The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience. Trustees serving during the year were: David Oxnam (Chair of Board of Trustees) Gayle Routledge Rachel Wilcox David Hobin Sarah Curtis

The Chief Executive is responsible for the day-to-day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 12 to the accounts.

Key Management Personnel during the year were: Ashley Ball-Gamble (Chief Executive) Gill Smitherman (Head of Fundraising) Claire Shinfield (Head of Engagement) Jeanette Hawkins (Chief Nurse)

STATEMENT OF TRUSTEES’ RESPONSIBILITIES

The trustees are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales and Scotland requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities (Accounts and Reports) Regulations 2008, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the charity’s constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam Chair of the board of trustees

Dated: 28 June 2023

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the ‘charity’) for the year ended 31 December 2022 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information contained within the trustees' report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on pages 9-10, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under these acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charity.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008, and Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

29 June 2023

Chartered Accountants Statutory Auditor West Walk Building 110 Regent Road Leicester LE1 7LT

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2022

Unrestricted
Restricted
funds
funds
2022
2022
Notes
£
£
Income from:
Donations and legacies
3
796,659
1,100,415
Charitable activities
4
347,166
6,061,600
Investments
5
5,935
-
Total
1,149,760
7,162,015
Expenditure on:
Raising funds
6
377,048
-
Charitable activities
7
872,045
6,524,842
Other
11
-
-
Total
1,249,093
6,524,842
Net (outgoing)/incoming resources before
transfers
(99,333)
637,173
Transfers between funds
(1,177)
1,177
Net (expenditure)/income for the year/
Net movement in funds
(100,510)
638,350
Reconciliation of funds
Total funds brought forward
591,470
1,331,587
Total funds carried forward
490,960
1,969,937		 Total
2022
£
1,897,074
6,408,766
5,935
8,311,775
377,048
7,396,887
-
7,773,935
537,840
-
537,840
1,923,057
2,460,897		 Total
2021
£
1,454,655
4,213,122
1,858
5,669,635
327,061
5,036,553
36,901
5,400,515
269,120
-
269,120
1,653,937
1,923,057

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2022

2022 2021
Notes £ £ £ £
Fixed assets
Tangible assets 14 42,486 41,442
Current assets
Stocks 15 53,029 35,426
Debtors 16 4,922,609 3,769,320
Cash at bank and in hand 4,025,410 4,047,115
9,001,048 7,851,861
Liabilities
Creditors: amounts falling due within one
year 17 (3,967,898) (3,395,160)
Net current assets 5,033,150 4,456,701
Total assets less current liabilities 5,075,636 4,498,143
Creditors: amounts falling due after
more than one year 18 (2,614,739) (2,575,086)
Total net assets 2,460,897 1,923,057
The funds of the charity
Restricted funds 20 1,969,937 1,331,587
Unrestricted funds 21 490,960 591,470
Total charity funds 2,460,897 1,923,057

The financial statements were approved and authorised for issue by the board of trustees on 28 August 2023 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)

Trustee

The notes on pages 17 - 31 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2022

Note
Cash flows from operating activities
Cash (absorbed by)/generated from
operations
25
Investing activities
Purchase of tangible fixed assets
Investment income received
Net cash used in investing activities
Net cash used in financing activities
Net (decrease)/increase in cash and cash
equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year		 2022
£
£
(13,527)
(14,113)
5,935
(8,178)
-
(21,705)
4,047,115
4,025,410		 2021
£
£
128,855
(10,123)
1,858
(8,265)
-
120,590
3,926,525
4,047,115

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (“FRS 102”), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Government grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

(Continued)

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Computer equipment, furniture and fixtures 5-10 years

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity’s activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.10 Financial instruments

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the Statement of Financial Activities.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows:

Allocation of support costs

The allocation of support costs is sensitive to changes in the level of work undertaken on each activity by the charity. The allocation is reassessed annually and amended when necessary to reflect current estimates.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

3
Income from donations and legacies
Unrestricted
Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2022
2022
2022
2021
2021
£
£
£
£
£
Donations
574,290
825,676
1,399,966
586,019
578,545
Legacies
222,369
33,417
255,786
103,190
150,000
Government grants
-
241,322
241,322
-
36,901
796,659
1,100,415
1,897,074
689,209
765,446
4
Income from charitable activities
Unrestricted Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2022
2022
2022
2021
2021
£
£
£
£
£
Registration fees for meetings
and other project expenditure
90,942
18,244
109,186
26,772
6,500
Member subscriptions and
publication payments
162,715
-
162,715
159,731
-
Grant income for research and
operations
93,509
5,964,095
6,057,604
59,850
3,907,695
CLIC Sargent chief nurse
funding
-
79,261
79,261
-
52,574
347,166
6,061,600
6,408,766
246,353
3,966,769
5
Income from investments
Unrestricted
Total
Unrestricted
funds
funds
2022
2022
2021
£
£
£
Interest
5,935
5,935
1,858		 3
Income from donations and legacies
Unrestricted
Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2022
2022
2022
2021
2021
£
£
£
£
£
Donations
574,290
825,676
1,399,966
586,019
578,545
Legacies
222,369
33,417
255,786
103,190
150,000
Government grants
-
241,322
241,322
-
36,901
796,659
1,100,415
1,897,074
689,209
765,446
4
Income from charitable activities
Unrestricted Restricted
Total
Unrestricted
Restricted
funds
funds
funds
funds
2022
2022
2022
2021
2021
£
£
£
£
£
Registration fees for meetings
and other project expenditure
90,942
18,244
109,186
26,772
6,500
Member subscriptions and
publication payments
162,715
-
162,715
159,731
-
Grant income for research and
operations
93,509
5,964,095
6,057,604
59,850
3,907,695
CLIC Sargent chief nurse
funding
-
79,261
79,261
-
52,574
347,166
6,061,600
6,408,766
246,353
3,966,769
5
Income from investments
Unrestricted
Total
Unrestricted
funds
funds
2022
2022
2021
£
£
£
Interest
5,935
5,935
1,858		 Total
2021
£
1,164,564
253,190
36,901
1,454,655
Total
2021
£
33,272
159,731
3,967,545
52,574
3,966,769 4,213,122
Total
2021
£
1,858

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

6
7		 Expenditure on raising funds
Unrestricted
Restricted
funds
funds
2022
2022
£
£
Costs of raising funds
Fundraising platform fees
24,576
-
Website
2,077
-
Fundraising, marketing
and publicity costs
188,604
-
Support costs (note 10)
161,791
-
377,048
-
Expenditure on charitable activities
Activities
undertaken
directly
Note 8
£
Support for research
110,551
Information for patients and families
51,789
Improving treatment and care
226,095
388,435
Unrestricted funds
Restricted funds		 Total
Unrestricted
funds
2022
2021
£
£
24,576
18,843
2,077
5,917
188,604
165,383
161,791
136,438
377,048
326,581
Grant
funding
Support
Costs
Note 9
Note 10
£
£
6,336,897
165,931
-
248,056
-
257,568
6,336,897
671,555		 Restricted
funds
2021
£
-
-
480
-
480
Total
2022
£
6,613,379
299,845
483,663
7,396,887
872,045
6,524,842
7,396,887		 Total
2021
£
18,843
5,917
165,863
136,438
327,061
Total
2021
£
4,480,854
259,557
296,142
5,036,553
697,984
4,338,569
5,036,553

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

8 Expenditure on activities undertaken directly

Support for
research
Information
for patients
and families
Improving
treatment
and care
£
£
£
Staff costs
97,944
-
-
Other tumour specific expenditure
10,530
-
-
Contact magazine expenses
-
20,360
-
Other publication expenses
-
28,312
-
Website
2,077
3,117
3,117
Cost of meetings
-
-
192,068
Travel expenses
-
-
11,729
Membership support costs
-
-
12,453
Other expenses
-
-
6,728
110,551
51,789
226,095
9
Expenditure on grant funding
Support for
research
Information
for patients
and families
Improving
treatment
and care
£
£
£
Grants to institutions:
University of Birmingham
939,992
-
-
Newcastle University
1,146,110
-
-
UCL Institute of Child Health
991,135
-
-
University of Nottingham
432,059
-
-
University of Bristol
401,433
-
-
Queen's University Belfast
(3,925)
-
-
Great Ormond Street
-
-
-
University of Glasgow
140,420
-
-
University of York
317,285
-
-
University of Cambridge
325,179
-
-
Institute of Cancer Research
210,885
-
-
University of Leeds
357,187
-
-
University of Manchester
(1,077)
-
-
University of Oxford
33,854
-
-
University College Dublin
-
-
-
Swansea University
-
-
-
University of Bath
-
-
-
The Royal Marsden Hospital
-
-
-
Blood Cancer UK
-
-
-
University of Leicester
112,515
-
-
Birmingham Children's Hospital
53,277
-
-
King's College London
850,659
-
-
The Open University
29,909
-
-
6,336,897
-
-		 Total
2022
£
97,944
10,530
20,360
28,312
8,311
192,068
11,729
12,453
6,728
388,435
Total
2022
£
939,992
1,146,110
991,135
432,059
401,433
(3,925)
-
140,420
317,285
325,179
210,885
357,187
(1,077)
33,854
-
-
-
-
-
112,515
53,277
850,659
29,909
6,336,897		 Total
2021
£
51,393
13,190
36,825
1,403
23,669
31,782
1,072
20,558
7,577
187,469
Total
2021
£
496,909
1,326,430
414,795
137,689
206,658
-
99,576
31,793
-
251,723
599,310
198,979
86,108
-
78,303
208,533
104,155
15,000
11,928
-
-
-
-
4,267,889

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

9 Expenditure on grant funding

(Continued)

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

Negative amounts represent an underspend on grants previously made returned to CCLG.

10 Expenditure on support costs

Expenditure on support costs
Basis of allocation
Staff costs
1
Depreciation & loss on disposal
1
Occupancy expenses
1
Postage
1
Staff training
1
Professional fees
1 / 2
Redundancy costs
1
Analysed between
Raising funds
Charitable activities		 2022
£
656,900
13,069
120,538
14,789
3,658
24,392
-
833,346
161,791
671,555
833,346		 2021
£
545,405
10,204
95,731
13,621
2,660
35,446
14,566
717,633
136,438
581,195
717,633
1 Support costs, excluding governance costs, have been allocated as follows:
Cost of raising funds
20% (2021 - 20%)
Charitable activities
Support for research
20% (2021 - 20%)
Information for patients and families
30% (2021 - 30%)
Improving treatment and care
30% (2021 - 30%)
2 Professional fees include governance costs of £24,392 (2021 - £35,446). Governance costs have been
allocated as follows:
Charitable activities
Support for research
17% (2021 - 17%)
Information for patients and families
22% (2021 - 22%)
Improving treatment and care
61% (2021 - 61%)

The amount charged to the SOFA in respect of auditor's remuneration was: - statutory audit £9,300 (2021 - £9,000) - other services £1,253 (2021 - £3,414)

11 Other expenditure

Restricted Total Restricted Total
funds funds
2022 2022 2021 2021
£ £ £ £
Wages - - 36,901 36,901

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

12 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year.

13 Employees

The average monthly number of employees during the year was:

Total
Employment costs
Wages and salaries
Social security costs
Other pension costs
Redundancy costs		 2022
Number
22
2022
£
633,405
63,204
58,235
-
754,844		 2021
Number
18
2021
£
530,285
51,546
51,868
14,566
648,265

The number of employees whose annual remuneration was more than £60,000 is as follows:

2022 2021
Number Number
£70,001 - £80,000 1 1
£90,001 - £100,000 1 -

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

14
Tangible fixed assets
Computer
equipment,
furniture
and fixtures
£
Cost
At 1 January 2022
73,325
Additions
14,113
At 31 December 2022
87,438
Depreciation and impairment
At 1 January 2022
31,883
Depreciation charged in the year
13,069
At 31 December 2022
44,952
Carrying amount
At 31 December 2022
42,486
At 31 December 2021
41,442
15
Stocks
2022
£
Merchandise stock
30,263
Educational literature
22,766
53,029		 Total
£
73,325
14,113
87,438
31,883
13,069
44,952
42,486
41,442
2021
£
14,483
20,943
35,426

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

16
Debtors
Amounts falling due within one year:
Trade debtors
Grant debtors
Rent deposit
Prepayments and accrued income
Accrued legacy income
Amounts falling due after more than one year:
Grant debtors
Total debtors
17
Creditors: amounts falling due within one year
Deferred income
Trade creditors
Grant creditors
Accruals
18
Creditors: amounts falling due after more than one year
Grant creditors		 2022
£
7,833
2,830,745
16,200
155,731
172,500
3,183,009
2022
£
1,739,600
4,922,609
2022
£
100
17,056
3,911,669
39,073
3,967,898
2022
£
2,614,739		 2021
£
81
2,349,235
16,200
130,113
205,000
2,700,629
2021
£
1,068,691
3,769,320
2021
£
-
55,830
3,293,878
45,452
3,395,160
2021
£
2,575,086

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised in unrestricted expenditure was £58,235 (2021 - £51,868).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

Balance at
1 January
2022
£
Tumour specific funds
1,112,573
CCLG Prize
54
General research fund
3,940
Adam Hay fund
11,102
CCLG Senior Members Group
7
PODC
4,782
POTG
210
The Little Princess Trust fund
6,200
Treatment Guidelines fund
18,225
TYAC Lisa Thaxter
44,132
Child Cancer Smart
72,867
PORT
420
CCLG Research Network
Partner Charity
42,467
Neuroblastoma Nursing Group
10,500
PODC - Iraq Fund
4,108
Young Lives vs Cancer Chief
Nurse Funding
-
Health Information
-
TYAC General Restricted
-
TYAC Research
-
Projects Restricted Fund
-
1,331,587		 Movement in funds
Income
Expenditure
£
£
761,793
(301,199)
310
-
2,000
(2,760)
120
-
-
-
1,114
-
8,350
(9,737)
5,639,669
(5,639,669)
-
(17,611)
-
(7,500)
5,000
(39,762)
-
-
324,425
(366,892)
-
-
4,276
-
79,261
(73,313)
27,375
(10,455)
1,000
-
66,000
-
241,322
(55,944)
7,162,015
(6,524,842)		 Transfers
Balance at
31 December
2022
£
£
-
1,573,167
-
364
-
3,180
-
11,222
-
7
-
5,896
1,177
-
-
6,200
-
614
-
36,632
-
38,105
-
420
-
-
-
10,500
-
8,384
-
5,948
-
16,920
-
1,000
-
66,000
-
185,378
1,177
1,969,937

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

Balance at
1 January
2021
£
Tumour specific funds
744,648
CCLG Prize
54
General research fund
3,940
Adam Hay fund
10,982
CCLG Senior Members Group
7
PODC
3,338
POTG
2,139
The Little Princess Trust fund
6,200
Treatment Guidelines fund
18,435
TYAC Lisa Thaxter
45,412
Child Cancer Smart
73,500
PORT
400
CCLG Research Network
Partner Charity
36,328
Neuroblastoma Nursing Group
10,500
Childhood Cancer Priority Setting
Partnership
17,909
PODC - Iraq Fund
1,530
Coronavirus Job Retention
Scheme
-
975,322		 Movement in funds
Income
Expenditure
£
£
780,510
(412,585)
-
-
-
-
120
-
-
-
1,444
-
2,947
(4,876)
3,907,695
(3,907,695)
-
(210)
-
(1,280)
-
(633)
20
-
-
6,139
-
-
-
(17,909)
2,578
-
36,901
(36,901)
4,732,215
(4,375,950)		 Transfers
Balance at
31 December
2021
£
£
-
1,112,573
-
54
-
3,940
-
11,102
-
7
-
4,782
-
210
-
6,200
-
18,225
-
44,132
-
72,867
-
420
-
42,467
-
10,500
-
-
-
4,108
-
-
-
1,331,587

Transfers have been made into restricted funds from unrestricted funds to underwrite a cash deficit on a fund.

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members’ Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

Young Lives vs Cancer Chief Nurse Funding

Funding for the Chief Nurse role and associated projects.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

Coronavirus Job Retention Scheme

Represents amounts received from the Government to cover staff costs during the Covid-19 pandemic.

Health Information

Funds received to support the production of health information for patients and families.

TYAC General Restricted

Fundraising and donations to support work specifically for teenagers and young adults with cancer.

TYAC Research

Income restricted to support research projects into teenage and young adult cancer.

Projects Restricted Funds

Income restricted to support specific projects including work related to research.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

21 Unrestricted funds

Movement in funds
Balance at
1 January
2022
Income Expenditure
£
£
£
General funds
591,470
1,149,760
(1,249,093)
Movement in funds
Balance at
1 January
2021
Income Expenditure
£
£
£
General funds
678,615
937,420
(1,024,565)
Analysis of net assets between funds
Unrestricted
Funds
2022
£
Fund balances at 31 December 2022 are represented by:
Tangible assets
42,486
Current assets/(liabilities)
448,474
Long term liabilities
-
490,960
Unrestricted
Funds
2021
£
Fund balances at 31 December 2021 are represented by:
Tangible assets
41,442
Current assets/(liabilities)
550,028
Long term liabilities
-
591,470		 Transfers
Balance at
31 December
2022
£
£
(1,177)
490,960
Transfers
Balance at
31 December
2021
£
£
-
591,470
Restricted
Funds
Total
2022
2022
£
£
-
42,486
4,584,676
5,033,150
(2,614,739)
(2,614,739)
1,969,937
2,460,897
Restricted
Funds
Total
2021
2021
£
£
-
41,442
3,906,673
4,456,701
(2,575,086)
(2,575,086)
1,331,587
1,923,057

22 Analysis of net assets between funds

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

23 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Within one year
Between two and five years		 2022
£
36,530
18,397
54,927		 2021
£
27,530
48,177
75,707

Amounts recognised in the SOFA as an expense during the period in respect of operating lease arrangements are £34,730 (2021 - £27,530).

24 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

2022 2021
£ £
Aggregate compensation 253,428 217,459

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 12 to the financial statements.

25
Cash generated from operations
2022
£
Surplus for the year
537,840
Adjustments for:
Investment income recognised in statement of financial activities
(5,935)
Depreciation and impairment of tangible fixed assets
13,069
Movements in working capital:
(Increase)/decrease in stocks
(17,603)
(Increase) in debtors
(1,153,289)
Increase in creditors
612,291
Increase in deferred income
100
Cash (absorbed by)/generated from operations
(13,527)		 2021
£
269,120
(1,858)
10,204
3,271
(663,738)
511,856
-
128,855

26 Analysis of changes in net funds

During the year the charity had no borrowings or obligations under finance leases. The changes in net funds of the charity therefore solely comprise of cash and cash equivalents.